J Endocr Soc 5(9):bvab084
DPP-4 Inhibitors As mentioned above, DPP-4 inhibitors are now an established and successful class of oral anti-hyperglycaemic agents, and are firmly embedded in guidelines for treating T2DM patients without atherosclerotic cardiovascular (CV) disease (116, 117)
This guide explains what patients need to know in 2026 to stay safe
Yet in the most recent month, from June to July 2025, AOM semaglutide prescribing increased by 4.9%, the largest one-month gain in first-time AOM semaglutide prescribing in over a year
For individuals who do not qualify for GLP-1 therapies or who need support in behavioral patterns rather than hunger alone, Contrave provides a reliable and clinically meaningful path toward improvement
There were as many deaths and more GI problems in those who took the diabetes drug compared with placebo